JP2015521465A5 - - Google Patents

Download PDF

Info

Publication number
JP2015521465A5
JP2015521465A5 JP2015516684A JP2015516684A JP2015521465A5 JP 2015521465 A5 JP2015521465 A5 JP 2015521465A5 JP 2015516684 A JP2015516684 A JP 2015516684A JP 2015516684 A JP2015516684 A JP 2015516684A JP 2015521465 A5 JP2015521465 A5 JP 2015521465A5
Authority
JP
Japan
Prior art keywords
sequence
nucleic acid
acid molecule
seq
factor viii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015516684A
Other languages
English (en)
Japanese (ja)
Other versions
JP6473416B2 (ja
JP2015521465A (ja
Filing date
Publication date
Priority claimed from GBGB1210357.8A external-priority patent/GB201210357D0/en
Application filed filed Critical
Publication of JP2015521465A publication Critical patent/JP2015521465A/ja
Publication of JP2015521465A5 publication Critical patent/JP2015521465A5/ja
Application granted granted Critical
Publication of JP6473416B2 publication Critical patent/JP6473416B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015516684A 2012-06-12 2013-06-12 第viii因子配列 Expired - Fee Related JP6473416B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1210357.8 2012-06-12
GBGB1210357.8A GB201210357D0 (en) 2012-06-12 2012-06-12 Factor VIII sequences
PCT/GB2013/051551 WO2013186563A2 (en) 2012-06-12 2013-06-12 Factor viii sequences

Publications (3)

Publication Number Publication Date
JP2015521465A JP2015521465A (ja) 2015-07-30
JP2015521465A5 true JP2015521465A5 (OSRAM) 2016-08-04
JP6473416B2 JP6473416B2 (ja) 2019-02-20

Family

ID=46605791

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015516684A Expired - Fee Related JP6473416B2 (ja) 2012-06-12 2013-06-12 第viii因子配列

Country Status (8)

Country Link
US (6) US9447168B2 (OSRAM)
EP (1) EP2859016B1 (OSRAM)
JP (1) JP6473416B2 (OSRAM)
AU (1) AU2013276247B2 (OSRAM)
CA (1) CA2875449A1 (OSRAM)
ES (1) ES2640586T3 (OSRAM)
GB (1) GB201210357D0 (OSRAM)
WO (1) WO2013186563A2 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
CA2931848A1 (en) 2013-12-09 2015-06-18 Sangamo Biosciences, Inc. Methods and compositions for genome engineering
CN108093639B (zh) * 2015-04-16 2022-07-19 埃默里大学 用于肝脏中蛋白质表达的重组启动子和载体及其用途
TWI841908B (zh) 2015-09-24 2024-05-11 美商拜奧馬林製藥公司 腺相關病毒因子viii載體、相關病毒粒子及包含其之治療調配物
SG11201804064WA (en) 2015-11-13 2018-06-28 Baxalta Inc Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
US10189888B2 (en) * 2015-11-13 2019-01-29 Baxalta Incorporated Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
MX2019000962A (es) 2016-07-26 2019-08-01 Biomarin Pharm Inc Novedosas proteinas de la capside del virus adenoasociado.
WO2019217513A2 (en) 2018-05-09 2019-11-14 Biomarin Pharmaceutical Inc. Methods of treating phenylketonuria
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
JP2021523198A (ja) 2018-05-14 2021-09-02 ビオマリン プハルマセウトイカル インコーポレイテッド 幼若対象におけるaavベクターの安定的発現
CA3106590A1 (en) 2018-07-16 2020-01-23 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
EP3923992A1 (en) 2019-02-15 2021-12-22 CRISPR Therapeutics AG Gene editing for hemophilia a with improved factor viii expression
BR112021015776A2 (pt) * 2019-06-05 2021-11-09 Bayer Healthcare Llc Edição de gene para hemofilia a com expressão de fator viii melhorada
CN112575034B (zh) * 2019-09-29 2023-04-25 济南赛尔生物科技股份有限公司 一种治疗a型血友病的产品及应用
EP4073106A2 (en) 2019-12-12 2022-10-19 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
KR20230078805A (ko) 2020-11-02 2023-06-02 바이오마린 파머수티컬 인크. 아데노-연관 바이러스의 농축 공정
WO2022264040A1 (en) 2021-06-14 2022-12-22 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
US20250381294A1 (en) 2022-01-14 2025-12-18 Anjarium Biosciences Ag Compositions of DNA Molecules Encoding Factor VIII, Methods of Making Thereof, and Methods of Use Thereof
WO2024007978A1 (zh) 2022-07-07 2024-01-11 深圳新诺微环生物科技有限公司 一种连接肽、包含连接肽的凝血八因子蛋白或其变体及其用途
WO2024238591A2 (en) 2023-05-15 2024-11-21 Biomarin Pharmaceutical Inc. Methods of treating anti-aav seropositive hemophilia patients
TW202517669A (zh) 2023-07-05 2025-05-01 日商武田藥品工業股份有限公司 用於A型血友病之基因療法的編碼表現增加之重組FVlll變異體的病毒載體

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818439B1 (en) * 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US6383794B1 (en) 1998-08-24 2002-05-07 Uab Research Foundation Methods of producing high titer recombinant adeno-associated virus
US20090148906A1 (en) 1998-09-29 2009-06-11 Shire Human Genetic Therapies, Inc. A Delaware Corporation Optimized messenger rna
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
DE60115613T2 (de) 2000-03-22 2006-08-24 Octagene Gmbh Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien
US7351813B2 (en) 2000-06-20 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Liver-specific gene expression cassettes, and methods of use
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
GB0325379D0 (en) 2003-10-30 2003-12-03 Oxford Biomedica Ltd Vectors
ES2381796T3 (es) 2004-09-22 2012-05-31 St. Jude Children's Research Hospital Expresión mejorada de Factor IX en vectores de terapia génica
CN1286981C (zh) 2004-11-30 2006-11-29 华中科技大学同济医学院附属同济医院 表达人类cyp2j2反义基因的重组腺相关病毒及其制备方法
US7943374B2 (en) * 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
US20090175833A1 (en) 2006-01-13 2009-07-09 Paula Dore-Duffy Pericytes for use as stem cells
EP2037892B1 (en) 2006-06-19 2015-03-18 Asklepios Biopharmaceutical, Inc. Modified factor viii and factor ix genes and vectors for gene therapy
US8512981B2 (en) 2006-06-21 2013-08-20 Amsterdam Molecular Therapeutics B.V. Vectors with modified initiation codon for the translation of AAV-Rep78 useful for production of AAV
DK2173888T3 (en) 2007-07-26 2016-11-28 Uniqure Ip Bv Baculovirus vectors comprising repeating coding sequences WITH differential preferred codons
WO2009017533A1 (en) 2007-07-27 2009-02-05 Porteon Electric Vehicles, Inc. Modular light vehicle chassis
JP5739865B2 (ja) * 2009-03-24 2015-06-24 バイエル・ヘルスケア・エルエルシー 第viii因子変異体および使用の方法
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
WO2011139629A2 (en) 2010-04-26 2011-11-10 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
AU2014318890B2 (en) 2013-09-12 2019-03-07 Biomarin Pharmaceutical Inc. Adeno-associated virus Factor VIII vectors

Similar Documents

Publication Publication Date Title
JP2015521465A5 (OSRAM)
JP7004328B2 (ja) 高形質導入効率rAAVベクター、組成物、および使用方法
JP2020518268A5 (OSRAM)
JP2011101646A5 (OSRAM)
JP2017532966A5 (OSRAM)
JP2013509168A5 (OSRAM)
FI3684423T3 (fi) Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä
RU2019111648A (ru) Средство лечения болезни гентингтона на основе aav
JP2014012022A5 (OSRAM)
JP2017536116A5 (OSRAM)
CN112040988A (zh) 修饰的aav衣壳多肽用于治疗肌肉疾病
JP2018534950A5 (OSRAM)
JP2020508685A5 (OSRAM)
JP2018138049A5 (OSRAM)
JP2018108113A5 (OSRAM)
JP2018520997A5 (OSRAM)
WO2013186563A3 (en) Factor viii sequences
JP2013027391A5 (OSRAM)
FI3889173T3 (fi) Optimoitu tekijä viii:n geeni
FI3313991T3 (fi) Muunnettu tekijä IX sekä koostumukset, menetelmät ja käytöt geeninsiirtoa varten soluihin, elimiin ja kudoksiin
CN108368164A (zh) CpG减少的因子VIII变体、组合物和方法以及用于治疗止血障碍的用途
FI3851537T3 (fi) Hyperbilirubinemian hoito
JP2010516252A5 (OSRAM)
CN107427557A (zh) 用于包装和表达变体因子viii以治疗血友病的改良表达组件
RU2017142006A (ru) Векторы на основе аденоассоциированных вирусов для лечения мукополисахаридозов